Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Active, not recruiting · NCT06160752 · Registry updated 2026-08-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations | Bone Diseases, Developmental, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Craniofacial Abnormalities, Limb Deformities, Congenital, Musculoskeletal Abnormalities, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, bone disorder, carcinoma, cholangiocarcinoma, craniosynostosis, dysostosis, epithelial neoplasm, intrahepatic cholangiocarcinoma, musculoskeletal system disorder, neoplasm, syndactyly, synostosis | Active, not recruiting | Phase 1 | 2026-08-05 | NCT06160752 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Tyra Biosciences, Inc | 7 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Massachusetts General Hospital | Boston | United States | 1015 |
| The Ohio State University | Columbus | United States | 191 |
| The University of Texas MD Anderson Cancer Center | Houston | United States | 207 |
| University of California San Francisco (UCSF) | San Francisco | United States | 13 |